Drugs / netarsudil-latanoprost
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07325240 | Nov 2025 → Jul 2027 expected | ocular hypertension, open-angle glaucoma | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | netarsudil-latanoprost | “netarsudil-latanoprost fixed combination ophthalmic solution 0.02%/0.005% in one eye” NCT07325240 ↗ |
| Route | Other | “netarsudil-latanoprost fixed combination ophthalmic solution 0.02%/0.005%” NCT07325240 ↗ |